AbCellera reports positive Phase 2 topline for ABCL635 in menopausal vasomotor symptoms

AbCellera Biologics announced positive topline Phase 2 results on 10 August 2026 for ABCL635, an antibody in development for moderate-to-severe vasomotor symptoms (VMS, hot flushes) associated with menopause, reporting a significant reduction in both the frequency and severity of VMS versus placebo alongside a favourable tolerability profile.

The company described best-in-class reductions in both frequency and severity of moderate-to-severe VMS after a single dose. ABCL635 is a non-hormonal, antibody-based candidate discovered on AbCellera's internal platform, representing the company's move from antibody-discovery partner to clinical-stage developer of its own programmes. Shares rose sharply on the data.

Source: AbCellera Biologics (Business Wire), 10 August 2026.